These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36898734)

  • 21. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
    Kringel R; Lamszus K; Mohme M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.
    Ohno M; Ohkuri T; Kosaka A; Tanahashi K; June CH; Natsume A; Okada H
    J Immunother Cancer; 2013; 1():21. PubMed ID: 24829757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
    Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
    Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
    An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
    Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
    Lin YJ; Mashouf LA; Lim M
    Front Immunol; 2022; 13():817296. PubMed ID: 35265074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
    Akhavan D; Subham S; Jeppson JD; Aguilar B; Wong RA; Hibbard JC; Hui S; Wong JYC; Forman SJ; Alizadeh D; Brown CE
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy.
    Yang F; Zhang D; Jiang H; Ye J; Zhang L; Bagley SJ; Winkler J; Gong Y; Fan Y
    Sci Transl Med; 2023 Feb; 15(683):eabq3558. PubMed ID: 36791206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
    Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.